ArticleIJU case reports2026
Successful Treatment of Paranasal Sinus Metastasis From Renal Cell Carcinoma With Immune Checkpoint Inhibitors and Radiotherapy: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Renal cell carcinoma (RCC) metastasis to the paranasal sinuses is rare and lacks standard treatment, particularly for unresectable tumors. We report a case of sphenoid sinus metastasis with sarcomatoid differentiation successfully managed with radiation therapy and immunotherapy. Case Presentation: A 59-year-old male who had undergone left radical nephrectomy for RCC 13 years prior presented with acute left eye pain and tinnitus. Contrast-enhanced computed tomography (CT) revealed a hyper vascular sphenoid sinus mass with osseous destruction. Biopsy confirmed metastatic RCC with sarcomatoid differentiation. Given rapid symptom progression, intensity-modulated radiation therapy (39 Gy in 13 fractions) was initiated, followed by immunotherapy with nivolumab and ipilimumab. The patient developed complete blindness, which gradually improved during treatment. Serial CT showed a partial response sustained through four cycles. Subsequent 37 cycles of maintenance nivolumab showed persisting tumor reduction. Conclusion: Radiation with nivolumab and ipilimumab may be effective for unresectable paranasal sinus metastases of RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.